Revisión sistemática sobre la administración de la quimioterapia en el período entre la quimiorradioterapia neoadyuvante y la cirugía en el cáncer de recto localmente avanzado.

Autores/as

  • Cristina Torres Arcos Cirugía General y Digestiva, Hospital Universitario Virgen Macarena. Sevilla.

DOI:

https://doi.org/10.26754/ojs_arcol/archcolo.202045024

Palabras clave:

neoplasia de recto, quimioterapia de consolidación, terapia neoadyuvante

Resumen

La quimiorradioterapia (QRT) preoperatoria seguida de la exéresis total mesorrectal y quimioterapia adyuvante son el tratamiento estándar actual para el cáncer de recto localmente avanzado. Esta estrategia no ha conseguido disminuir el riesgo de metástasis a distancia de aproximadamente un 30%. El tratamiento adyuvante tiene tasas de cumplimiento poco satisfactorias, y tampoco ha demostrado mejorar la supervivencia. Surgen estudios para evaluar la administración de la quimioterapia en el período comprendido entre la QRT y la cirugía para intentar mejorar los resultados.

Citas

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer [Internet]. 2013 [cited 2018 Nov 28];49:1374–403. Available from: http://dx.doi.org/10.1016/j.ejca.2012.12.027

Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol [Internet]. 2094 [cited 2018 Nov 30];19:799–825. Available from: http://redecan.org/es/index.cfm

Cercek A, Campbell ;, Roxburgh SD, Strombom P, Smith ; J Joshua, Temple LKF, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer Invited Commentary Supplemental content Downloaded From: by a Biblioteca Virtual de Ciencias de la Salud de Castilla La Mancha User on 11/27/2018. JAMA Oncol [Internet]. 2018 [cited 2018 Nov 30];4(6):180071. Available from: https://bvsspa.gtbib.net/sod/usu/BV-SSPA/documentos/%21CRISTINA.TOR1_%21%21BV-SSPA-CA_13813177_2236794_473.pdf

Hoerske C, Weber K, Goehl J, Hohenberger W, Merkel S. Long-term outcomes and quality of life after rectal carcinoma surgery. Br J Surg [Internet]. 2010 Aug [cited 2018 Nov 30];97(8):1295–303. Available from: http://doi.wiley.com/10.1002/bjs.7105

Wibe A, Moller B NJ et al. A national strategic change in treatment policy for rectal cancer: implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002;45:857–866.

Birbeck KF, Macklin CP TN et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235:449–57.

Improved Survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–7.

Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet (London, England). 2009;373:811–20.

Sauer R, Becker H, Hohenberger W et al. Preoperative versus post-operative chemoradiotherapy for rectal cancer. New Engl J Med. 2004;351:1731–1740.

Roh MS, Colangelo LH, O’Connell MJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124–30.

Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(1926–1933.).

Cercek A, Goodman K, C CH et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12:513–9.

Kuebler JP, Wieand HS, O’Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.

Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116.

Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: An emerging option. Cancer. 2017;123(9):1497–506.

Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.

Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2007;25:4379–86.

Bosset JF, Calais G, Mineur L et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.

Sainato A, Cernusco Luna Nunzia V, Valentini V et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223–9.

Glynne-Jones R, Counsell N, Quirke P et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neo-adjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25:1356–62.

Breugom AJ, van Gijn W, Muller EW et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26:696–701.

Bujko K, Glimelius B, Valentini V, Michalski W SM. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery 6 a fluoropyrimidine and surgery 1 a fluoropyrimidine 6 oxaliplatin. Eur J Surg Oncol. 2015;41:713–23.

Palta M, Czito BG WC. Colorectal cancer: adjuvant chemotherapy for rectal cancer, an unresolved issue. Nat Rev Clin Oncol. 2014;11:182–4.

Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defi ned poor-risk rectal cancer: a phase 2 trial. Lancet Oncol [Internet]. 2010 [cited 2018 Nov 23];11:241–8. Available from: www.thelancet.com/oncology

Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer. J Clin Oncol [Internet]. 2006 [cited 2018 Dec 4];24:668–74. Available from: www.jco.org

Chua YJ CD. Emerging therapies for rectal cancer. Color Dis. 2006;8 (Suppl 3:18–20.

Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: Results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009;52(12):1927–34.

Zampino MG, Magni E, Leonardi MC, Petazzi E, Santoro L, Luca F, et al. CAPECITABINE INITIALLY CONCOMITANT TO RADIOTHERAPY THEN PERIOPERATIVELY ADMINISTERED IN LOCALLY ADVANCED RECTAL CANCER. Radiat Oncol Biol [Internet]. 2009 [cited 2018 Dec 10];75:421–7. Available from: https://ac.els-cdn.com/S0360301608036912/1-s2.0-S0360301608036912-main.pdf?_tid=ac30b40f-0a97-478d-a675-f5e4c0b8c870&acdnat=1544457196_0176b07e1b32d018caa187c624c1666c

Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254(1):97–102.

Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D, et al. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma [Internet]. 2013 [cited 2018 Dec 10]. Available from: http://www.ro-journal.com/content/8/1/130

Gao Y-H, Lin J-Z, An X, Luo J-L, Cai M-Y, Cai P-Q, et al. Clinical Investigation Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial Radiation Oncology. Radiat Oncol Biol [Internet]. 2014 [cited 2018 Dec 10];90(5):1153–60. Available from: http://dx.doi.org/10.1016/j.ijrobp.2014.07.021

Gao Y-H, Zhang X, An X, Gao Y-H, Zhang · X, An · X, et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol [Internet]. 2014 [cited 2018 Dec 10];190:158–64. Available from: https://link.springer.com/content/pdf/10.1007%2Fs00066-013-0500-5.pdf

Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: A multicentre, phase 2 trial. Lancet Oncol [Internet]. 2015;16(8):957–66. Available from: http://dx.doi.org/10.1016/S1470-2045(15)00004-2

Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryn J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol [Internet]. 2016 [cited 2018 Dec 10];27:834–42. Available from: https://academic.oup.com/annonc/article-abstract/27/5/834/2769824

Tang J, Wu X, Bai Y, Gao Y, Jiang W, Kong L, et al. Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer. J Cancer [Internet]. 2018 [cited 2018 Dec 10];9(8):1365–70. Available from: http://www.jcancer.org

Biagi JJ, Raphael MJ, Mackillop WJ et al: Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA. 2011;305:2335–42.

Maré Chal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol [Internet]. 2012 [cited 2018 Nov 23];23:1525–30. Available from: https://academic.oup.com/annonc/article-abstract/23/6/1525/168502

Schou J V., Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol. 2012;

Gollins S S-MD. Neoadjuvant treatment strategies for locally advanced rectal cancer. col (R Coll Radiol). 2016;28(146–151).

Hofheinz RD, Wenz F, Post S et al. Chemo- radiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(579–588).

O’Connell MJ, Colangelo LH, Beart RW E, Al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;(32):1927–34.

An X, Lin X, Wang FH et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer. 2013;49:843–51.

Aschele C, Cionini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.

Rödel C, Liersch T, Becker H et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fl uorouracil and oxaliplatin versus fl uorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. 2012; 13: Lancet Oncol. 2012;13:679–87.

O’Connell MJ, Colangelo LH, Beart RW et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34.

Nilsson PJ, van Etten B, Hospers GAP, Påhlman L, van de Velde CJH, Beets-Tan RGH, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer - the RAPIDO trial. BMC Cancer. 2013;13.

Zeng W-G, Zhou Z-X, Liang J-W et al. Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome. J Surg Oncol. 2014;110:463–67.

Calvo FA, Morillo V, Santos M et al. Interval between neoadjuvant treatment and defi nitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes. J Cancer Res Clin Oncol. 2014;140:1651–60.

Kerr SF, Norton S G-JR. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity with- out compromising prognosis. Br JSurg. 2008;95(12):1534–1540.

Descargas

Publicado

2020-12-23

Número

Sección

Revisiones